Literature DB >> 28153089

Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b.

Rachid El Fatimy1, Shruthi Subramanian1, Erik J Uhlmann1, Anna M Krichevsky2.   

Abstract

Glioblastoma (GBM) brain tumor remains among the most lethal and incurable human diseases. Oncogenic microRNA-10b (miR-10b) is strongly and universally upregulated in GBM, and its inhibition by antisense oligonucleotides (ASOs) reduces the growth of heterogeneous glioma cells; therefore, miR-10b represents a unique therapeutic target for GBM. Here we explored the effects of miR-10b gene editing on GBM. Using the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system, we investigated effects of miR-10b gene editing on the growth of cultured human glioma cells, tumor-initiating stem-like cells, and mouse GBM xenografts, as well as the oncogene-induced transformation of normal astrocytes. We show that GBM is strictly "addicted" to miR-10b and that miR-10b gene ablation is lethal for glioma cell cultures and established intracranial tumors. miR-10b loss-of-function mutations lead to the death of glioma, but not other cancer cell lines. We have not detected escaped proliferative clones of GBM cells edited in the miR-10b locus. Finally, neoplastic transformation of normal astrocytes was abolished by the miR-10b-editing vectors. This study demonstrates the feasibility of gene editing for brain tumors in vivo and suggests virus-mediated miR-10b gene ablation as a promising therapeutic approach that permanently eliminates the key regulator essential for tumor growth and survival.
Copyright © 2017 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR-Cas9; brain tumor; cancer; gene editing; genome editing; glioblastoma; microRNA-10b; ncRNA; orthotopic animal models; therapy

Mesh:

Substances:

Year:  2017        PMID: 28153089      PMCID: PMC5368404          DOI: 10.1016/j.ymthe.2016.11.004

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  36 in total

1.  Guidelines for the design and statistical analysis of experiments using laboratory animals.

Authors:  Michael F W Festing; Douglas G Altman
Journal:  ILAR J       Date:  2002

2.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

3.  Efficient, complete deletion of synaptic proteins using CRISPR.

Authors:  Salvatore Incontro; Cedric S Asensio; Robert H Edwards; Roger A Nicoll
Journal:  Neuron       Date:  2014-08-21       Impact factor: 17.173

Review 4.  The miR-10 microRNA precursor family.

Authors:  Disa Tehler; Nina Molin Høyland-Kroghsbo; Anders H Lund
Journal:  RNA Biol       Date:  2011-09-01       Impact factor: 4.652

Review 5.  Genome editing. The new frontier of genome engineering with CRISPR-Cas9.

Authors:  Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2014-11-28       Impact factor: 47.728

6.  MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10.

Authors:  Lihua Sun; Wei Yan; Yingyi Wang; Guan Sun; Hui Luo; Junxia Zhang; Xiefeng Wang; Yongping You; Zhengxiang Yang; Ning Liu
Journal:  Brain Res       Date:  2011-03-16       Impact factor: 3.252

7.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

8.  Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy.

Authors:  Peter C Huszthy; Tsanan Giroglou; Oleg Tsinkalovsky; Philipp Euskirchen; Kai Ove Skaftnesmo; Rolf Bjerkvig; Dorothee von Laer; Hrvoje Miletic
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

9.  Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting.

Authors:  Gregory W Goldberg; Wenyan Jiang; David Bikard; Luciano A Marraffini
Journal:  Nature       Date:  2014-08-31       Impact factor: 49.962

10.  Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic.

Authors:  Nadiya M Teplyuk; Erik J Uhlmann; Galina Gabriely; Natalia Volfovsky; Yang Wang; Jian Teng; Priya Karmali; Eric Marcusson; Merlene Peter; Athul Mohan; Yevgenya Kraytsberg; Ron Cialic; E Antonio Chiocca; Jakub Godlewski; Bakhos Tannous; Anna M Krichevsky
Journal:  EMBO Mol Med       Date:  2016-03-01       Impact factor: 12.137

View more
  27 in total

1.  High-throughput microRNA profile in adult and pediatric primary glioblastomas: the role of miR-10b-5p and miR-630 in the tumor aggressiveness.

Authors:  Luiz Guilherme Darrigo Junior; Mirella Baroni; Régia Caroline Peixoto Lira; Silvia Teixeira; Paola Fernanda Fedatto; Vanessa Silva Silveira; Veridiana Kill Suazo; Luciana Chain Veronez; Rodrigo Alexandre Panepucci; David Santos Marco Antônio; José Andres Yunes; Silvia Regina Brandalise; Simone Dos Santos Aguiar; Luciano Neder; Ricardo Santos de Oliveira; Hélio Rubens Machado; Carlos Gilberto Carlotti; Luiz Gonzaga Tone; Elvis Terci Valera; Carlos Alberto Scrideli
Journal:  Mol Biol Rep       Date:  2020-09-04       Impact factor: 2.316

Review 2.  Multidimensional communication in the microenvirons of glioblastoma.

Authors:  Marike L Broekman; Sybren L N Maas; Erik R Abels; Thorsten R Mempel; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Rev Neurol       Date:  2018-08       Impact factor: 42.937

3.  MicroRNA Alterations in Induced Pluripotent Stem Cell-Derived Neurons from Bipolar Disorder Patients: Pathways Involved in Neuronal Differentiation, Axon Guidance, and Plasticity.

Authors:  Monica Bame; Melvin G McInnis; K Sue O'Shea
Journal:  Stem Cells Dev       Date:  2020-06-17       Impact factor: 3.272

Review 4.  The Role of Non-coding RNAs in Oncology.

Authors:  Frank J Slack; Arul M Chinnaiyan
Journal:  Cell       Date:  2019-11-14       Impact factor: 41.582

5.  Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold.

Authors:  Matteo Zurlo; Romeo Romagnoli; Paola Oliva; Jessica Gasparello; Alessia Finotti; Roberto Gambari
Journal:  Int J Mol Sci       Date:  2022-05-26       Impact factor: 6.208

6.  Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma.

Authors:  Evgeny Deforzh; Erik J Uhlmann; Eashita Das; Aleksandra Galitsyna; Ramil Arora; Harini Saravanan; Rosalia Rabinovsky; Aditya D Wirawan; Nadiya M Teplyuk; Rachid El Fatimy; Sucika Perumalla; Anirudh Jairam; Zhiyun Wei; Leonid Mirny; Anna M Krichevsky
Journal:  Mol Cell       Date:  2022-04-06       Impact factor: 19.328

Review 7.  microRNA-based diagnostic and therapeutic applications in cancer medicine.

Authors:  Lorenzo F Sempere; Asfar S Azmi; Anna Moore
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-05-17       Impact factor: 9.957

Review 8.  Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs.

Authors:  Dinh-Duc Nguyen; Suhwan Chang
Journal:  Int J Mol Sci       Date:  2017-12-27       Impact factor: 5.923

Review 9.  In vivo genome editing thrives with diversified CRISPR technologies.

Authors:  Xun Ma; Avery Sum-Yu Wong; Hei-Yin Tam; Samuel Yung-Kin Tsui; Dittman Lai-Shun Chung; Bo Feng
Journal:  Zool Res       Date:  2018-03-18

10.  Voltage-gated potassium channel blocker 4-aminopyridine induces glioma cell apoptosis by reducing expression of microRNA-10b-5p.

Authors:  Qin Ru; Wei-Ling Li; Qi Xiong; Lin Chen; Xiang Tian; Chao-Ying Li
Journal:  Mol Biol Cell       Date:  2018-03-22       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.